AbbVie Suggests Humira Will Retain Leading Position In 2023

Ahead Of US Biosimilar Competition On Adalimumab Kicking Off Later This Month

 
• By David Wallace
Formation of paper planes with a single red plane leading
AbbVie expects Humira to retain a leading position this year • Source: Shutterstock

More from Biosimilars

More from Products